NCT01694407View on ClinicalTrials.gov

Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

HIV

Interventions

DRUG

Tenofovir (TFV) Alone Vaginal Tablet

vaginal tablet containing 40 mg of TFV

DRUG

Emtricitabine (FTC) Alone Vaginal Tablet

Vaginal Tablet containing 40 mg of TFV

DRUG

TFV and FTC Combined Vaginal Tablet

vaginal tablet with 40 mg TFV and 40 mg FTC

DRUG

Placebo Vaginal Tablet

Vaginal Tablet containing no drug

Trial Locations (2)

10451

Albert Einstein College of Medicine, The Bronx

23507

Clinical Research Center, Eastern Virginia Medical School, Norfolk

All Listed Sponsors

lead

CONRAD

OTHER

NCT01694407 - Safety, Pharmacokinetics, Pharmacodynamics, and Disintegration Time of Vaginal Tablets Containing Tenofovir and/or Emtricitabine | Biotech Hunter | Biotech Hunter